Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up-Reference-Cited by-同舟云学术

Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up

Published:2016-06-27 Issue:1 Volume:28 Page:348-358
ISSN:1046-6673
Container-title:Journal of the American Society of Nephrology
language:en
Short-container-title:JASN

Author:

Dahan Karine,Debiec Hanna,Plaisier Emmanuelle,Cachanado Marine,Rousseau Alexandra,Wakselman Laura,Michel Pierre-Antoine,Mihout Fabrice,Dussol Bertrand,Matignon Marie,Mousson Christiane,Simon Tabassome,Ronco Pierre

Publisher

American Society of Nephrology (ASN)

Subject

Nephrology,General Medicine

Reference31 articles.

1. Glomerular Diseases: Membranous Nephropathy—A Modern View

2. M-Type Phospholipase A2Receptor as Target Antigen in Idiopathic Membranous Nephropathy

3. Treatment of idiopathic membranous nephropathy

4. Rituximab in Primary Membranous Nephropathy: First-Line Therapy, Why Not?

5. Prognosis of Untreated Patients with Idiopathic Membranous Nephropathy

Cited by 292 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. B cell dysregulation and depletion therapy in primary membranous nephropathy: Prospects and potential challenges;International Immunopharmacology;2024-10

2. NELL-1 Associated Membranous Nephropathy: A case report of Lipoic Acid-Induced Nephrotic Syndrome;2024-09-11

3. Therapeutic targets in membranous nephropathy: plasma cells and complement;Clinical Kidney Journal;2024-08-13

4. Obinutuzumab as Initial or Second-Line Therapy in Patients With Primary Membranous Nephropathy;Kidney International Reports;2024-08

5. Advances in primary glomerulonephritis;British Journal of Hospital Medicine;2024-07-30